Cedar rapids top companies

The rapid rebound of China's V-shaped economic recovery since the second half of 2020 and improvement in the business environment will continue to make the domestic market attractive for foreign investment, a policy adviser said. Jiang Ying, a member of the 13th National Committee of the Chinese People's Political Consultative Conference, spoke about economic and other issues she expects to see during the two sessions in March, the annual meetings of China's top legislature and top political advisory body. She said she expects a GDP growth rate for 2021 of about 7.5 percent and a double-digit rate in the first quarter. The global recovery is starting to speed up enough to boost China's exports in 2021. But investment, which recovered strongly last year, may not see a sustainable boom this year as the government may be reluctant to promote growth by raising the debt level, according to Jiang, who is also vice-chairwoman of Deloitte China, an international consulting company. ... » Learn More about Policy adviser: China to remain attractive to foreign investors

The Comprehensive Agreement on Investment, once inked by the European Union and China, will become an important milestone for the two major economies. To some extent, the CAI, on which the two sides wrapped up negotiations on Dec 30, can be considered more important than a trade agreement for the EU. We (at Deutsche Bank) believe the CAI will likely boost EU investment in China. For EU manufacturers, China's move to further widen market access and remove shareholding limits will likely help create new opportunities and build a level playing field for domestic and foreign investors. Perhaps the service sector can be expected to make even greater progress after the two sides sign the agreement. EU subsidiaries in China accounted for 11 percent of the total manufacturing sales, but only 3 percent of services sales of EU subsidiaries worldwide. By further opening up China's financial and information technology services－as well as promising sectors such as environment and health ... » Learn More about China-EU investment deal more vital than FTA

More American consumers have turned to plant-based meat substitutes since the pandemic, and now some of the biggest fast-food chains in the US – including McDonald's — will source the products with producers. The popular plant-based meat alternative company Beyond Meat signed a new partnership with McDonald's last week, a vital step in the growing shift to take meat alternatives into the dining mainstream in the country. The company will be the preferred supplier for a new plant-based burger dubbed the "McPlant"and work with McDonald's to develop new substitutes for pork, chicken and egg. It also signed a new contract with fast-food giant Yum Brands, which owns and operates brands like KFC, Pizza Hut and Taco Bell, to supply new plan-based protein items as substitute options. "We're excited about the long-term potential plant-based protein menu items have to attract more customers to our brands, especially younger consumers," Chris Turner, Yum Brands CFO said in a company ... » Learn More about Meatless products hit stride in pandemic

#Corona Vaccine COVID-19 recovered people showing faster antibody response to Covishield vaccine #Corona Vaccine Get a dose 24x7 at your convenience: Govt removes time constraint for getting Covid-19 shot #Corona Vaccine Coronavirus cases: India records 14,989 new COVID-19 cases, 98 fresh fatalities in past 24 hours #Corona Vaccine List of side effects of Covishield and Covaxin #Corona Vaccine Centre allows states to take call on converting more private hospitals into vaccine sites #Corona Vaccine TMC writes to EC over PM Modi’s photo on Covid-19 vaccination doc For Quick Alerts Subscribe Now India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 6 min ago Jan Sangh founded by Bengal's son, still Mamata calls BJP 'outsider party': Nitin Gadkari ... » Learn More about India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

EV charging solutions provider Magenta Power on Wednesday announced the setting up of its first set of street lamp integrated charger ChargeGrid Flare, in partnership with HPCL. The facility has initially been installed at HPCL outlets in two locations in the Bandra Kurla Complex of Bandra suburb of Mumbai, and the other one at Niti Marg in New Delhi, Magenta said in a release. Designed exclusively to offer an energy-efficient streetlight combined with an EV charging point, the charger provides integrated EV charging facilities from within a durable, traditional-looking, streetlight, the company said. It also said it is looking to set up over 1,000 such facilities by this year. The ChargeGrid Flare is a smartly built, inclusive of power saving efficient LED lamp, robust street light pole and electric vehicle supply equipment made for Indian climatic conditions enabling online and remote monitoring of the chargers, said the release. It has automated payment gateway ... » Learn More about Magenta Power sets up street lamp integrated EV charging stations

India-made COVID-19 vaccine Covaxin has demonstrated an interim clinical efficacy of 81% in its Phase 3 clinical trial, vaccine maker Bharat Biotech said. Covaxin has demonstrated high clinical efficacy trend against COVID-19 as well as significant immunogenicity against the rapidly emerging variants, CMD Krishna Ella said. A statement from Bharat Biotech, which developed the vaccine in collaboration with Indian Council of Medical Research (ICMR), said 25,800 participants between 18-98 years of age were enrolled for the Phase 3 study. It included 2,433 over the age of 60 and 4,500 with comorbidities. The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus seven cases observed in the Covaxin group, resulting in a point estimate of vaccine efficacy of 80.6%. Also read: Coronavirus | Hyderabad CSIR lab helped develop key molecule for Covaxin The interim analysis included a preliminary review of the safety ... » Learn More about Bharat Biotech says COVID-19 vaccine Covaxin shows 81% efficacy in Phase 3 clinical trials